ESR1 and neoplasm: After adjustment with tumor size, lymph node status, ER, PR, HER2, and endocrine therapy, we founded that participants with GG genotype appeared a higher recurrence risk compared with patients with AG or AA genotype, which indicated that rs12075 was a significant prognostic marker under dominant models (AG+AA vs GG: HR = 0.54, 95% CI: 0.31‐0.93, P = 0.027).